[Acute pulmonary edema during general anesthesia in a young woman treated with epirubicin].
L Kidmose, Stolberg Ef
Abstract
L Kidmose, Stolberg Ef
Abstract
The use of the anthracycline doxorubicin is restricted by its cardiac toxicity. Another anthracycline, epirubicin, is probably less cardiotoxic. A case is reported, where a 30 year-old woman with breast cancer, treated with epirubicin, developed pulmonary oedema during surgery and anaesthesia. The patient had no previous cardio-pulmonary disorders, and had only received 10% of the usual maximum dose of epirubicin. The different clinical presentations of anthracycline-induced cardiac toxicity are described.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The use of the anthracycline doxorubicin is restricted by its cardiac toxicity. Another anthracycline, epirubicin, is probably less cardiotoxic. A case is reported, where a 30 year-old woman with breast cancer, treated with epirubicin, developed pulmonary oedema during surgery and anaesthesia. The patient had no previous cardio-pulmonary disorders, and had only received 10% of the usual maximum dose of epirubicin. The different clinical presentations of anthracycline-induced cardiac toxicity are described.
Key concepts: Epirubicin, Anthracycline, Medicine, Doxorubicin, Anesthesia, Cardiotoxicity, Pulmonary edema, Toxicity